Sumitomo Dainippon Pharma Annual Report 2017
10/102

Business Model for Value CreationSocial issuesValue creation processBusiness Model——Value Creation ProcessSumitomo Dainippon Pharma will continue to organically integrate our capital resources, pursue innovative processes in all of our businesses, and create value.At the same time, we spell out the social responsibilities that each process needs to fulll as we address CSR.CSR ManagementResearch & developmentSources of value creationBusiness activitiesSee p. 19 for details.See p. 33 for details.See p. 51for details.Manufactured capitalManufactured capitalFinancial capital•Stable and robust nancial base, primarily from Japan and North AmericaUnmet medical needsThere are unmet medical needs, including diseases for which no therapeutics exist as well as diseases for which therapeutics are not fully satisfactory.Issues related to healthcare accessThere are regions and countries where residents do not have equal access to necessary healthcare for reasons including poverty and inadequate healthcare systems.Human capitalFostering human resources to take on the challenges of the future (DSP Academy)Promoting diversication targeting active participation by a varied work forceStriving to improve employee satisfaction (DSP Opinion)•••Social and relationship capitalTrust from patients and general publicTrust from medical institutions and business partners••Natural capitalEnvironmental resources related to our business activitiesInitiatives to minimize environmental burdens from our business activities••••Intellectual capitalPatents, licenses, and other intellectual propertyResearch and development capabilities for discovering new pharmaceuticalsProduction bases able to engage in stable manufacturingResearch laboratories with leading-edge technologyGlobal supply chain••••••Focus therapeutic areas: Psychiatry & Neurology and Oncology. Also focus on disease elds where no approved drugs exist, in addition to the Regenerative Medicine and Cell Therapy eldResearch activity striving to discover innovative pharmaceuticals through our research laboratories (with their leading-edge technology) and through active collaboration with research institutions inside and outside JapanUnder our ONE TEAM operating structure for Global Clinical Development linking our Japan and U.S. units, conduct efcient development focused on late-stage clinical development productsMarketing•••Japan: Further strengthen sales capacity in focus areas, and build a highly efcient sales organization that can exibly respond to changing local healthcareNorth America: further growth for antipsychotic agent LATUDA® and antiepileptic APTIOM®, and expand sales in the Chronic Obstructive Pulmonary Disease (COPD) area by launching new productsChina: maximize prots from existing products and establish a highly efcient business foundation09Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#10

このブックを見る